

Isha Dhungana, MD, PhD

Neurology Unit
Kathmandu Neuro Center and Polyclinic
Kathmandu

Prabin Shrestha, MD, PhD

Department of Neurosurgery
Norvic International Hospital
Kathmandu

Address for correspondence:

Isha Dhungana, MD, PhD
Neurology Unit
Kathmandu Neuro Center and Polyclinic
Kathmandu
Email: pshisha2001@yahoo.com

Received, 16 April, 2015

Accepted, 21 April, 2015

Role of Botulinum toxin injection in neurological problems: A Short Review

Botulinum Toxin (BoNT), a neurotoxin known for many years for its lethal nature has been in use for many cosmetic purposes for last many years. Its use in many medical problems especially chronic neurological problems has been well established in recent years. BoNT is a useful symptomatic treatment for many neurological disorders, and is emerging as one of the leading modes of treatments in the new subspecialty in neurology called “Interventional neurology.” We have also been using BoNT regularly for therapeutic purposes in different neurological diseases with good success rate for last few years. We think use of BoNT-A needs to be encouraged in our country to provide relief to the patients suffering from many of the chronic disabling neurological problems.

Key Words: botulinum toxin, hemifacial spasm, spasticity

We have been hearing about the Botulinum Toxin injections for quite some time now. Commercialized cosmetic usage has been widely marketed not only globally, but also in our country in recent years. But medical use of Botulinum toxin is lagging far behind in our practice.

What is Botulinum toxin?

Botulinum Neurotoxin (BoNT) is a neurotoxic protein produced by the bacterium *Clostridium botulinum* and related species. BoNT is one of the most poisonous biological substances known and is also called ‘Miracle Poison’. History shows the lethal poisoning outbreaks due to consumption of botulinum contaminated food stuffs like sausages.¹³ It had been once designed to be used as biological weapon during the World War II time.³²

Botulism still is a deadly illness which can result from ingestion, enteric bacterial overgrowth, or wound infection. Food-borne botulism causes regular outbreaks with symptoms ranging from mild diplopia to muscle weakness and respiratory compromise.³⁶ The typical syndrome of descending weakness resulting from intramuscular injections can occur due to contamination of intravenous drugs by *Clostridium* spores are present in soil (wound botulism).⁵ Infantile botulism can result from ingestion of *Clostridium* spores and is a cause of acquired hypotonia.³⁴

Despite its dangerous nature, BoNT has been extensively studied and now is an established modality of treatment for various problems. Therapeutic use of Botulinum toxin was started in the late 1960s by Dr. Alan B. Scott, an ophthalmologist to correct strabismus, initially injected extraocular muscles in rhesus monkey and later in humans. Further various studies showed efficacy

Dhungana et al

of Botulinum toxin in the treatment of muscle control syndromes like blepharospasm and cervical dystonias.

In 1989, the US Food and Drug Administration (FDA) approved BoNT for treatment of blepharospasm, strabismus, and facial nerve dysfunction. In 2000, cervical dystonia became an FDA-approved indication for both serotypes A and B of botulinum neurotoxin. Current FDA-approved uses of BoNT-A also include the reduction of glabellar lines and the treatment of axillary hyperhidrosis. Today, Botulinum neurotoxin (BoNT) can be injected to achieve therapeutic benefit across a large range of clinical conditions in almost all medical subspecialties.¹⁴ In 2002, the FDA approved the use of Botulinum toxin-A for the cosmetic purpose of temporarily reducing glabellar forehead frown lines. Since then use of BoNT-A for various cosmetic and therapeutic indications are surging up by each passing day.

Discussion

How BoNT works?

The anaerobic bacillus *Clostridium botulinum* secretes seven known serotypes of botulinum toxin, typed alphabetically A–G.²⁵ Botulinum neurotoxins reduce presynaptic outflow of acetylcholine, the principal neurotransmitter, at the neuromuscular junction, with a consequent diminution in muscle contraction leading to functional paralysis of the muscle injected with BoNT. Botulinum toxins act at four different sites in the body: The neuromuscular junction, autonomic ganglia, postganglionic parasympathetic nerve endings and postganglionic sympathetic nerve endings that release acetylcholine.^{16, 37} The peak of the paralytic effect occurs four to seven days after injection. The affected nerve terminals do not degenerate, but the blockage of neurotransmitter release is irreversible. Functions recover by the sprouting of nerve terminals and formation of new synaptic contacts which usually takes two to three months. Thus, the functional paralysis usually lasts for 3–4 months.¹¹

There are two main commercial types: botulinum toxin type A and botulinum toxin type B. Doses of all commercially available botulinum toxins are expressed in terms of units of biologic activity. One unit of botulinum toxin corresponds to the calculated median intraperitoneal lethal dose (LD₅₀) in female Swiss-Webster mice. There are reported cases around 5-15% that developed secondary nonresponsiveness due to the production of neutralizing antibodies.^{2, 10} Injecting more than 200 units per session and repeat or booster injections given within one month of treatment increases the risk of development of neutralizing antibodies. The lowest dose of toxin necessary to achieve the desired clinical effect should be used and reinjection

within one month should be avoided to keep antibody formation as low and unlikely as possible. It is produced commercially for medical, cosmetic, and research use.

Many practitioners have chosen to administer injections under the guidance of electromyograph (EMG) monitoring. This technique involves using a 27-gauge EMG needle connected to an EMG recorder. The injection is placed where the maximal EMG recording can be found within the muscle. This technique ensures that the injection is at the point of the muscle that is contributing the most to the muscle activity. With routine injections and practice many centers have obtained satisfactory results without EMG guidance.²⁸

Few side effects, both serious and more benign have been reported with BoNT-A administration. As injections are local, intramuscular systemic complications are rare. Injection for cervical dystonia might cause dysphagia and increased risk of aspiration pneumonias and injections for strabismus might lead to ptosis and diplopia.⁴ Other adverse events include cough, fever, upper respiratory infection, flu-like malaise, headache, and very commonly, injection site reactions (erythema, swelling) and bruising. Hypersensitivity reactions such as edema and dyspnea have been also noted. One case of anaphylaxis has been reported. Similarly spontaneous death after Botox injection has been reported but no clear causal relation proven. A meta-analysis of controlled trials for BoNT efficacy in a variety of conditions concluded that focal weakness localized to the area of injection were the only consistent events which were not reflected in controls.²⁶ Generally, these events were mild to moderate in severity, temporary, and related to the medication's mechanism of action.

BoNT in Neurological problems

Although botulinum toxin is one of the most deadly neurotoxins known, the therapeutic administration of BoNT-A is quite safe. Botulinum neurotoxins act through a multistep process which involves binding to nerve terminals followed by internalization and inhibition of release of calcium-dependent neurotransmitters.

A local injection of botulinum toxin is a well-accepted treatment for focal dystonias, hemifacial spasms and strabismus. Its use by skilled neurologists has been reported to be safe and effective for the treatment of certain movement disorders¹⁵, including blepharospasm, hemifacial spasm, oromandibular dystonia, cervical dystonia¹², focal limb dystonias²², laryngeal dystonia, tics, and essential tremor.¹⁹ Because of its action at the neuromuscular junction leading to reversible alteration in muscle tone and selective functional denervation of muscles, BoNT is used extensively in disorders of muscle overactivity, such as facial movement disorders, limb and

neck dystonias, and spasticity. Botulinum neurotoxins are also effective at inhibiting acetylcholine release at sites other than neuromuscular junction, leading to effective treatments for hypersecretory syndromes, especially hypersalivation and hyperhidrosis. Apart from these, recently, painful syndromes such as chronic migraine headache, low back pain, trigeminal neuralgia and some chronic conditions that respond only partially to medical treatment are also being treated with success by BoNT-A injections. It seems to be a promising alternative to some surgical interventions like sphincterotomy in patients with chronic anal fissures and detrusor overactivity. The list of possible new indications is rapidly expanding. BoNT-A for perioperative pain, treatment for amputation stump-related and phantom-limb pain, plantar fasciitis, carpal tunnel related-pain, and even refractory restless-legs syndrome are being reported.

Effective management of blepharospasm with BoNT-A was established largely via small, uncontrolled, open-label trials³³ before United States FDA approval. Review of pooled case-controlled data of over 2500 patients demonstrated a 90% efficacy rate of BoNT-A injections in blepharospasm.²⁰ A meta-analysis involving BoNT-A revealed only one single well-designed, prospective, blinded, placebo-controlled trial of 11 patients, in addition to many larger open-label trials, and concluded that the medication is safe in HFS and supported the conclusions of other uncontrolled studies that efficacy ranges from 76%–100%.^{6,39} Peak effect was reported at 2 weeks and effect duration was nearly 3 months.³⁹

Many clinical trials of BoNT-A have focused largely on occupational dystonias, especially writer's cramp¹⁸. Most studies were open-label, case-controlled, or reports of clinical experience with a number of patients. In one double-blinded, placebo-controlled trial, 12/20 patients with writer's cramp sufferers experienced improved pen control after BoNT-A injections, but only 4/20 noted improved writing ability.³⁸ A prospective study of 47 patients assessed after BoNT-A injection concluded that patients with forearm pronation and flexion dystonias had the most improvement of their writer's cramp symptoms.⁸ Clinical experience suggests that most patients (75%–80%) have onset of benefit one week following BoNT-A injection with peak at two weeks, and effect lasting for around 3 months.⁷ Leg and foot dystonias are far less common and less well-studied. Case series of primary foot dystonia patients showed improvement to repeated BoNT-A injections in 6/8.

Central nervous system disorders with upper motor neuron dysfunction often produce spasticity and hypertonia of the limb.²¹ The muscles most prominently affected are those innervated by the pyramidal tracts. In the upper

extremities, the shoulder adductors, elbow flexors, wrist pronators, finger and thumb flexors are most involved. In the lower extremities, hip adductors, knee extensors, and ankle plantar flexors and inverters may have increased spastic tone.²⁹ The most common causes of such spasticity in adults are trauma, stroke, and multiple sclerosis, while in children, cerebral palsy (CP) is the primary cause. Similar to dystonias, oral medications may have some benefit on such spasticity, but produce sedation or other cognitive side effects.⁹

In this regard, BoNT-A has been studied widely as a spasticity treatment in adults. Most studies have assessed pre- and post-treatment muscle tone via Ashworth scores. Many were performed in conjunction with electrical stimulation, and physical or occupational therapies. Brashear et al and Simpson have reported Upper limb tone improvement in blinded, placebo-controlled studies with 200–300U BoNT-A.^{3,37} Similarly Lower extremity tone improved in spastic patients after BoNT-A injection, especially hip adductors and calf spasticity.^{17,23} Various studies and experiences show that motor function may be improved in a select subgroup of patients who retain selective motor control and some degree of dexterity in important distal muscles, require injection of relatively few target muscles, and especially if combined with other interventions such as extensive physical therapy post injection.³⁵ For better results, consideration must be made of the total number of muscles to be injected and the maximum recommended dose per injection session.

In 2002, Micheli et al reported the successful treatment of a patient with hemifacial spasm associated with TN with onabotulinumtoxin A, which opened up new possibilities for its use.²⁴ After that, several other open-label trials have examined the preventive effects of BTX-A on TN with good results.^{24, 27, 1, 30} It has been reported that direct infusion of botulinum toxin-A *in vivo* has shown to inhibit enzymes responsible for hippocampal cell death following induced seizures in rats. This shows that in addition to its role at the neuromuscular junction and peripheral nerve, BoNT-A may be a neuroprotective agent for the central nervous system also.^{15,28} With all the current interest, speculation and ongoing researches in botulinum neurotoxins, we can expect emergence of exciting newer therapeutic applications to come to light in the days to come.

Thus, BoNT is a useful symptomatic treatment for many neurological disorders, and is emerging as one of the leading modes of treatments in the new subspecialty in neurology called "Interventional neurology."¹⁴ A precise knowledge and understanding of the functional anatomy of the muscles is absolutely necessary to correctly use botulinum toxins in clinical practice. Adverse effects of

Dhungana et al

BoNT are usually mild and transient. The most common complication is excessive or unwanted weakness but this resolves as the action of the toxin is lost.

In our experience, we have used botulinum toxin-A injections successfully in variety of neurological problems like poststroke spasticity, blepharospasm, hemifacial spasm, cervical dystonias, chronic migraine, trigeminal neuralgia, writer's cramp with very good results. Use of BoNT-A needs to be encouraged in our country to provide relief to the patients suffering from many of the chronic disabling neurological problems.

References

1. Allam N, Brasil-Neto JP, Brown G et al. Injections of botulinum toxin type A produce pain alleviation in intractable trigeminal neuralgia. **Clin J Pain** **21**:182–184, 2005
2. Anderson TJ, Rivest J, Stell R, Steiger, et al. Botulinum toxin treatment of spasmodic torticollis. **Journal Royal Society of Medicine** **85**: 524–529, 1992
3. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. **N Engl J Med** **347**: 395–400, 2002
4. Comella CL, Thompson PD. Treatment of cervical dystonia with botulinum toxins. **Eur J Neurol** **13**: 16–20, 2006
5. Cooper JG, Spilke CE, Denton M, et al. Clostridium botulinum: an increasing complication of heroin misuse. **Eur J Emerg Med** **12**: 251–252, 2005
6. Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type A therapy for hemifacial spasm. **Cochrane Database Syst Rev** **1**: CD004899, 2005c
7. Das CP, Dressler D, Hallett M. Botulinum toxin therapy of writer's cramp. **Eur J Neurol** **13**: 55–59, 2006
8. Djebbari R, du Montcel ST, Sangla S, et al. Factors predicting improvement in motor disability in writer's cramp treated with botulinum toxin. **J Neurol Neurosurg Psychiatry** **75**: 1688–1691, 2004
9. Dones I, Nazzi V, Broggi G. The guidelines for the diagnosis and treatment of spasticity. **J Neurosurg Sci** **50**: 101–105, 2006
10. Dressler D, Dirnberger G. Botulinum toxin therapy: risk factors for therapy failure. **Mov Disord** **15**: 51, 2000
11. Duchen LW. An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibers of the mouse. **J Neurol Sci** **14**:47–60, 1971
12. Dutton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. **Surv Ophthalmol** **41(1)**: 51-65, 1996
13. Erbguth FJ. Historical note on the therapeutic use of botulinum toxin in neurological disorders. **J Neurol Neurosurg Psychiatry** **60**: 151, 1996
14. Giladi N, Meer J, Kidan C, Greenberg E, Gross B, Honigman S. Interventional neurology: botulinum toxin as a potent symptomatic treatment in neurology. **Isr J Med Sci** **30(11)**: 816-819, 1994
15. Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, Jankovic J. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. **Toxicon** **67**: 94-114, 2013
16. Hay JC. SNARE complex structure and function. **Exp Cell Res** **271**: 10-21, 2001
17. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. **J Neurol Neurosurg Psychiatry** **68**: 707-712, 2000
18. J J M Kruisdijk, J H T M Koelman, B W Ongerboer de Visser, R J de Haan, J D Speelman. Botulinum toxin for writer's cramp: a randomised, placebocontrolled trial and 1-year follow-up. **J Neurol Neurosurg Psychiatry** **2007**;78:264-270, 2007
19. John P N, Kevin R J. Neurologic uses of botulinum neurotoxin type A. **Neuropsychiatr Dis Treat** **3(6)**: 785-798, 2007
20. Jost WH, Kohl A. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. **J Neurol** **248**: 21-24, 2001
21. Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. **Neurology** **30**: 1303-1313, 1980
22. Leonardo G Cohen, Mark Hallett, Bruce D Geller, Fred Hochberg. Treatment of focal dystonias of the hand with botulinum toxin injections. **J Neurol Neurosurg Psychiatry** **52**: 355-363, 1989
23. Mancini F, Sandrini G, Moglia A, et al. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (BOTOX) for the treatment of spastic foot. **Neurol Sci** **26**: 26-31, 2005
24. Micheli F, Scorticati MC, Raina G. Beneficial effects of botulinum toxin type A for patients with painful tic convulsivus. **Clin Neuropharmacol** **25**: 260-262, 2002
25. Montecucco C, Schiavo G, Rosetto O. The mechanism of action of tetanus and botulinum neurotoxins. **Arch**

- Toxicol 18:** 342-354, 1996
26. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. **Curr Med Res Opin 20:** 20:981-990, 2004
 27. Ngeow WC, Nair R. Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109(3):** e47-50, 2010
 28. Nigam P K, Nigam A. Botulinum Toxin. **Indian J Dermatol 55(1):** 8-14, 2010
 29. Pathak MS, Nguyen HT, Graham HK, et al. Management of spasticity in adults: practical application of botulinum toxin. **Eur J Neurol 13:** 42-50, 2006
 30. Piovesan EJ, Teive HG, Kowacs PA et al An open study of botulinum- A toxin treatment of trigeminal neuralgia. **Neurology 65:**1306-1308, 2005
 31. Ramirez-Castaneda J, Jankovic J . Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. **Toxicon 90:** 344-348, 2014
 32. Schantz EJ, Johnson EA. Botulinum toxin: the story of its development for the treatment of human disease. **Perspect Biol Med 40:** 317-327, 1997
 33. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of the extraocular muscles. **Invest Ophthalmol 12:** 924-927,1973
 34. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. **Ann Intern Med 129:** 221-228, 1998
 35. Sheean GL. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? **Curr Opin Neurol 14:** 771-776, 2001
 36. Silberstein S. Botulinum neurotoxins: origins and basic mechanisms of action. **Pain Practice 4:** S19-26, 2004
 37. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. **J Pharm Exp Ther 212:** 16-21, 1980
 38. Tsui JK, Bhatt M, Calne S, et al. Botulinum toxin in the treatment of writer's cramp: a double-blind study. **Neurology 43:** 183-185, 1993
 39. Yoshimura DM, Aminoff MJ, Tami TA, et al. Treatment of hemifacial spasm with botulinum toxin. **Muscle Nerve 15:** 1045-1049,1992